Buonerba, C.; Dolce, P.; Iaccarino, S.; Scafuri, L.; Verde, A.; Costabile, F.; Pagliuca, M.; Morra, R.; Riccio, V.; Ribera, D.;
et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers 2020, 12, 408.
https://doi.org/10.3390/cancers12020408
AMA Style
Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D,
et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 2020; 12(2):408.
https://doi.org/10.3390/cancers12020408
Chicago/Turabian Style
Buonerba, Carlo, Pasquale Dolce, Simona Iaccarino, Luca Scafuri, Antonio Verde, Ferdinando Costabile, Martina Pagliuca, Rocco Morra, Vittorio Riccio, Dario Ribera,
and et al. 2020. "Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis" Cancers 12, no. 2: 408.
https://doi.org/10.3390/cancers12020408
APA Style
Buonerba, C., Dolce, P., Iaccarino, S., Scafuri, L., Verde, A., Costabile, F., Pagliuca, M., Morra, R., Riccio, V., Ribera, D., De Placido, P., Romeo, V., Crocetto, F., Longo, N., Imbimbo, C., De Placido, S., & Lorenzo, G. D.
(2020). Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 12(2), 408.
https://doi.org/10.3390/cancers12020408